I listened to the ASM..... basic blocking and tackling and building the biz... they have folks that know what they are doing and putting the platform together.... takes time but I think they are getting there.... my second take was there is no urgency to create a higher sp? no desire to promote progress of IP...
If you are setting up team w/ options and readjusting workforce participation per mention in last call, a lower sp works for the interim... given the past crew really took care of themselves in option land and avid was probably the red haired stepchild, it could be a smart move to get folks some equity going forward.... helps in retention also i think accumulation is going on while under the radar...
I heard confirmation of three commercial process validations... per last two cc's, they were completed for existing clients halo and roche... halo had three phase 3's close to the commercialization phase.... darzelex sc... filed w fda july, roche's phase 3 success and filing early 2020 and halo's own drug w/ celgene... readout in dec....
Darzelex is already a $4 bil drug w/ 4 hr infusion times... the sc version should fly of the shelves with 5 min infusion time and capture a big chunk of mkt share... and Janssen has 6 phase 3's with Halo going on and numerous other clients w/ trials...
So the real inflection point won't happen until more visibility on the halo activity.... given the mention of downstream capabilities with regard to client needs, fill and finish could be in the cards...
So we are six months out but we also have a larger institutional base and more analyst coverage that will sniff out the progress as it unfolds.. all imo
